Opinion|Videos|May 1, 2024
DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.
OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
3
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
4
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
5